Provided by Tiger Trade Technology Pte. Ltd.

Soleno Therapeutics

30.05
-1.8100-5.68%
Post-market: 32.902.85+9.48%18:43 EDT
Volume:1.76M
Turnover:52.96M
Market Cap:1.55B
PE:77.05
High:32.37
Open:31.73
Low:29.43
Close:31.86
52wk High:90.32
52wk Low:29.43
Shares:51.62M
Float Shares:44.87M
Volume Ratio:1.11
T/O Rate:3.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3900
EPS(LYR):0.3900
ROE:6.01%
ROA:2.09%
PB:3.45
PE(LYR):77.05

Loading ...

Soleno Therapeutics Faces Investor Lawsuit Over Alleged Safety Concealment in VYKAT XR Drug Launch

TIPRANKS
·
Mar 23

Class Action Lawsuit Targets Soleno Therapeutics Over Alleged Securities Law Violations

Reuters
·
Mar 20

Sector Update: Health Care

MT Newswires Live
·
Mar 19

Soleno Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Mar 19

Soleno Therapeutics Seen Beating 2026 Sales Estimates Despite Slower Vykat XR US Launch, Oppenheimer Says

MT Newswires Live
·
Mar 18

Soleno Therapeutics price target lowered to $80 from $110 at Oppenheimer

TIPRANKS
·
Mar 18

Soleno Therapeutics publishes corporate presentation on VYKAT XR launch and USD 190.4 million sales

Reuters
·
Mar 18

Soleno Therapeutics faces securities class action over DCCR safety disclosures

Reuters
·
Mar 16

Soleno Therapeutics adopts amended and restated bylaws effective March 16, 2026

Reuters
·
Mar 16

Cantor Fitzgerald Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)

TIPRANKS
·
Mar 13

Soleno Therapeutics faces class action over DCCR trial disclosures after 27% stock drop

Reuters
·
Mar 12

Soleno Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Mar 10

Soleno Therapeutics Files Initial Beneficial Ownership Statement for CFO Jennifer Fulk

Reuters
·
Mar 05

Soleno Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 04

Soleno Therapeutics price target lowered to $100 from $120 at H.C. Wainwright

TIPRANKS
·
Mar 04

Stock Track | Soleno Therapeutics Soars 5.43% in Post-Market Trading After Wells Fargo Maintains Overweight Rating

Stock Track
·
Feb 28

Soleno Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Feb 28

Soleno Therapeutics price target lowered to $110 from $114 at Wells Fargo

TIPRANKS
·
Feb 27

Soleno Therapeutics’ Risky Bet on VYKAT XR: Commercial, Regulatory, and Funding Hurdles Threaten Path to Profitability

TIPRANKS
·
Feb 27

Stock Track | Soleno Therapeutics Plummets 11.88% After TD Cowen Slashes Price Target

Stock Track
·
Feb 26